News and Materials
AREVA Med Brochure
Macrocyclics 2017 Product Catalog
AREVA Med: Developing Nuclear Medicine for Tomorrow’s Cancer Treatments
AREVA Med is a nuclear biotech company developing innovative therapies in oncology. AREVA Med has developed new processes for producing lead-212 (212Pb), a rare radioactive isotope used in Targeted Alpha Therapy (TAT), an innovative and promising approach of nuclear medicine allowing to recognize and destroy cancer cells while limiting the impact on nearby healthy cells. With its partners, AREVA Med pursues the development of effective therapies to address cancer patients’ needs. AREVA Med is the medical subsidiary of the AREVA group.